NKG2D CAR-NK Cell Therapy (Suxi Biopharmaceutical)

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameNKG2D CAR-NK Cell Therapy (Suxi Biopharmaceutical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNKG2D ligands modulatorsNatural killer cell replacements
TargetsNKG2D ligands
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHangzhou Suxi Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Suxi Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A